Sunday, November 24, 2024
Subscribe American Journal of Medicine Free Newsletter
infectious diseaseHIVTransient Loss of HIV-1 DNA in an HIV-1 Positive Patient After Kidney...

Transient Loss of HIV-1 DNA in an HIV-1 Positive Patient After Kidney Transplantation: A Case Report

Transient loss of HIV DNA after ATG therapy for kidney transplantation. CD4 T-cell count (blue, left axis) and CD4 T-cell percentage of all T cells (orange, right axis) were quantified, and qualitative HIV DNA measured in the peritransplant period.

Solid organ transplantation is increasingly used in human immunodeficiency virus (HIV) patients and is accumulating favorable outcomes from kidney and liver transplants in HIV-1 positive patients.1, 2

Antithymocyte globulin (ATG) is used for prevention and treatment of acute rejection following renal transplantation.3 It promotes T-cell depletion as well as modulation of cell surface antigens.4 It is possible that this agent may indirectly target and reduce the latent HIV-1 reservoir5 and reactivate the latent reservoir.6

Here, we report a case of an HIV-1 positive patient who demonstrated a transient clearance of the proviral DNA after receiving ATG as induction immunosuppression post kidney transplant.

Case Report

A 53-year-old man with end-stage renal disease was referred to our institution for kidney transplant evaluation. He was diagnosed with HIV-1 infection 12 years prior with a CD4 T-cell count above 450 cells/ mcl and undetectable HIV-1 viral load for more than 6 years on zidovudine, abacavir, and efavirenz therapy.

The patient underwent deceased donor kidney transplantation. Induction immunosuppression with ATG was used given concern for increased allograft rejection risk due to underlying HIV infection. He also received corticosteroids, mycophenolate, and tacrolimus through the peri- and posttransplant period. Antiretroviral therapy was continued, and the regimen was intensified with raltegravir, which has been shown to reduce HIV-1 reservoir size in some7, 8 but not all trials.9, 10

HIV-1 proviral DNA was measured serially in whole blood pre- and posttransplant using the Amplicor HIV-1 DNA Test, version 1.5 (Roche Molecular Systems Inc., Branchburg, NJ). In addition, the CD4 T-cell count and plasma HIV-1 RNA viral load were obtained (Figure 1).

To read this article in its entirety please visit our website.

-Ana C. Paim, MD, Stacey A. Rizza, MD, Andrew D. Badley, MD, Mikel Prieto, MD, Sandra J. Taler, MD, Pearlie P. Chong, MD, MSCR, Nathan W. Cummins, MD

This article originally appeared in the October issue of The American Journal of Medicine.

Latest Posts

lupus

Sarcoidosis with Lupus Pernio in an Afro-Caribbean Man

A 54-year-old man of Afro-Caribbean ancestry presented with a 2-month history of nonproductive cough, 10-day history of constant subjective fevers, and a 1-day history...
Flue Vaccine

Flu Vaccination to Prevent Cardiovascular Mortality (video)

0
"Influenza can cause a significant burden on patients with coronary artery disease," write Barbetta et al in The American Journal of Medicine. For this...
varicella zoster

Varicella Zoster Virus-Induced Complete Heart Block

0
Complete heart block is usually caused by chronic myocardial ischemia and fibrosis but can also be induced by bacterial and viral infections. The varicella...
Racial justice in healthcare

Teaching Anti-Racism in the Clinical Environment

0
"Teaching Anti-Racism in the Clinical Environment: The Five-Minute Moment for Racial Justice in Healthcare" was originally published in the April 2023 issue of The...
Invisible hand of the market

The ‘Invisible Hand’ Doesn’t Work for Prescription Drugs

0
Pharmaceutical innovation has been responsible for many “miracles of modern medicine.” Reliance on the “invisible hand” of Adam Smith to allocate resources in the...
Joseph S. Alpert, MD

New Coronary Heart Disease Risk Factors

0
"New Coronary Heart Disease Risk Factors" by AJM Editor-in Chief Joseph S. Alpert, MD was originally published in the April 2023 issue of The...
Cardiovascular risk from noncardiac activities

Cardiac Risk Related to Noncardiac & Nonsurgical Activities

0
"Assessment of Cardiovascular Risk for Noncardiac and Nonsurgical Activities" was originally published in the April 2023 issue of The American Journal of Medicine. Cardiovascular risk...